Doing my post-doctoral studies at Servier offered an ideal transition from academic research to the private sector. I had the opportunity to work on a program to discover new medicines with a therapeutic purpose.
Partnering with Servier
open innovation
We are committed to working alongside our partners over the long term
The best way to achieve fast-paced innovation oriented to meet patient needs is through collaboration and constant dialogue between those involved in health care in both the public and private sectors. That is why Servier takes an open and collaborative approach to innovation.
We are committed to working alongside our partners over the long term.
Servier harnesses open innovation to draw on collective intelligence in a way that benefits patients
At Servier, we understand the importance of open innovation. We consider it presents three main advantages—accelerate the speed of research, offer each project an optimal environment in which to thrive, and collaborate with the best partners for each project.
We believe in fostering synergy between shared expertise and harnessing the interdependence of our knowledge and savoir faire.
To effectively respond to the challenges and priorities facing our Group, we leverage cross-fertilization made possible by an international workforce that boasts complementary, cross-disciplinary expertise; and open innovation through the partnerships and collaboration we encourage between our R&D teams and external organizations, especially in the main innovation hubs throughout the world.
A partner of choice
Our partnership strategy centers around a single objective to ramp up the speed with which we develop treatments that significantly improve patients’ quality of life. We take a people-oriented approach to our partnerships, and we focus on creating win-win situations by pooling our expertise. We are keen to invest in innovation that benefits patients in the future.
Submit a proposal
Do you have a proposal that aligns with our partnering interests? Contact a member of our team or fill out this form.
Our value proposition
When it comes to successful partnerships, our value proposition is unique.
Our governance model underpinned by independence enables us to adopt a long-term vision to build lasting, effective relations, guaranteeing stability for all our partners.
We have developed expertise in international markets and a diverse network of geographic locations, boasting a presence in both mature and emerging markets. We are therefore in a position to establish a personalized approach to collaboration with each partner so as to optimize every dimension of the relationship to benefit all parties.
We draw on the scientific excellence for which our teams are renowned and the considerable investment in R&D to build a high quality and future facing portfolio of therapeutic projects. Our flexible, reliable and agile teams work day in, day out to drive scientific progress. We are a partner of choice.
70
Over 70 strategic alliances and research collaborations currently active
Watch these case studies
Day in, day out, we expand and diversify our network of partners.
#PartnerOfChoice Servier x Aitia
What if an AI-based technology existed that could help treat pancreatic cancer? This is the rationale behind our collaboration with Aitia, the leader in the development and application of causal AI and digital twins to discover the next generation of breakthrough medicines for neurodegenerative diseases and oncology.
Find out more – Digital Twins: When AI drives progress for the pharmaceutical industry
00:00 / 00:00
#PartnerOfChoice Servier x Celsius Therapeutics
We established a partnership with Celsius Therapeutics in 2020 to identify and approve new drug targets to treat bowel cancer.
00:00 / 00:00
#PartnerOfChoice Servier x Oncodesign
Initiated in March 2019, our collaboration with Oncodesign, a French biotech specialized in precision medicine, has identified the LRRK2 kinase inhibitors and their potential to act as therapeutic agents against Parkinson’s disease.
00:00 / 00:00
#PartnerOfChoice Servier x Vernalis
We have partnered with the biotech Vernalis Research since 2007, working together on several projects focusing on a range of drug targets to drive progress in oncology research.
00:00 / 00:00
Start-ups
When we work with start-ups, we inject fresh momentum and stimulate value creation for both parties with a shared goal to boost therapeutic innovation to serve patient needs.
In Saclay, Spartners by Servier & BioLabs, the start-up incubator for therapeutic innovation
Ranked among the world’s top eight innovation clusters, including Silicon Valley, Beijing, Boston and Israel’s Silicon Wadi, the Plateau Paris-Saclay enjoys a first-rate international reputation. The campus is home to key players in research, international companies and start-ups, as well as schools and universities of excellence.
The start-up incubator, Spartners by Servier & BioLabs, housed within our Research and Development Institute in Paris-Saclay, is unique in France. Operated by BioLabs, the leader in shared laboratories, Spartners by Servier & BioLabs is designed to accommodate around 15 start-ups, or over 100 scientists, in a 1,850 sqm building. Spartners by Servier & BioLabs offers shared or private laboratories, fully equipped with state-of-the-art facilities, enabling selected residents to benefit from the best equipment to accelerate their development.
We take care of equipment maintenance, train residents in its use, manage laboratories from A to Z, and provide access to a single purchasing platform, all of which make daily life easier for entrepreneurs, enabling them to accelerate the growth of their businesses. This working environment is complemented by a large number of events on site, as well as in the international BioLabs network. A definite advantage for residents, who have access to a veritable innovation community of over 300 start-ups worldwide.
15
start-ups can be hosted at Spartners by Servier & BioLabs
Do you work for a start-up and want to join the incubator?
If you represent a digital health start-up, visit the “Digital health” tab.
A Golden Ticket competition for start-ups and biotechs
In 2024, we launched the first Golden Ticket competition in partnership with BioLabs. The prize: a year’s free incubation including a bench with access to a full range of equipment and an office at Spartners by Servier & BioLabs.
Are incubators innovation boosters for start-up?
Since 2022, Servier has sponsored a start-up to help it join the California Life Science program’s FAST Fall cohort (FAST CLS). A godsend for young life science start-ups!
“WeHealth by Servier”: Digital innovations for health care
Our ambition by 2030 is to be an agile organization and a Digital Performer. One of the paths to achieving this is to improve health care professionals’ and patients’ engagement through an omnichannel approach and “beyond the pill” therapeutic solutions. With these innovative digital solutions and services, our goal is to improve the monitoring, prediction and prevention of disease progression by providing personalized care.
WeHealth by Servier is the embodiment of our digital health strategy, intended for two key players: start-ups and incubators. It is part of a dynamic of open innovation and will focus on developing various partnerships – co-development, licenses, strategic partnerships – based on recognition of our team’s expertise around the world.
A digital strategy for our therapeutic areas
In our different therapeutic areas, we are pursuing a differentiated strategy based on the specificities and patient needs.
In cardiometabolism and venous diseases, we are maintaining our unwavering commitment to patients, with the development of innovative digital services focused in particular on improving therapeutic adherence and awareness. The My Health Partner website and Elfie application are two examples.
In oncology, neuroscience and immuno-inflammation, we are working on new digital health projects to support health care professionals, to develop initiatives that will improve patient quality of life and enable patients to access targeted treatments that are more suited to their profile.
Please contact the team for collaboration opportunities or to identify an incubator in our network that can host your digital health start-up.
If you would like to be immersed in the start-up incubator, Spartners by Servier & BioLabs, hosted at our Research and Development Institute in Paris-Saclay, visit the “Start-ups” tab.
When digital technology is used to serve patient needs
In 2022, we signed a partnership agreement with the Singaporean start-up Elfie. Its mobile application of the same name helps patients monitor chronic diseases, encouraging better adherence to treatment.
Digital tech as a super power to serve patient needs: read our article
Universities
Boosting innovation through scientific knowledge
We work with the most prestigious universities and surround ourselves with top talent. We support young researchers and work as part of a community to drive therapeutic innovation. By combining our strengths, we can meet the challenges of the future.
We build on strategic alliances with institutions and universities to work with new scientific data and innovative technologies. In particular, we have developed partnerships with several universities all throughout the world, including Harvard, Montreal, Hong Kong, Hamburg and Vienna.
In France, our future Research and Development Institute at Paris-Saclay will work in close collaboration with the most prestigious universities, including Centrale Supélec, École polytechnique, École normale supérieure Paris-Saclay and Université Paris-Saclay, the first university in France in the Shanghai ranking.
Investing in the excellence of academic research
We strongly believe that innovation is the key to therapeutic progress. That is why we build on academic excellence so as to continually better serve patients. Each year, Servier takes on around 60 PhD and postdoctoral researchers. Half of our research efforts are conducted in our R&D centers, while the other half is integrated into our partner labs.
Read our article: A PhD in pharma industry: a unique opportunity for young talents
+70
Over 70 PhD and post-doctoral students across 10 countries
Spotlight on the SHINEDocs program
We work closely to support young researchers through our SHINEDocs program,1 which accompanies them through their PhD or post-doctoral studies. This enables them to expand their network, develop their soft skills and present their research. Consequently, they all become active participants in therapeutic projects and innovative technology.
Testimonial
Meet Selena Bouffette, PhD student at Servier
Selena Bouffette was one of the winners of Seedpods Day 2023. This event brings together doctoral and post-doctoral students working at Servier or in a partner laboratory. Their challenge? Present their research project to an audience of experts from the private sector, academics and public partners.
00:00 / 00:00
Ready to express your talent for therapeutic progress?
Servier Campus, our website designed especially for students and graduates
[1] Servier Highlighting Innovation through its NEtwork of PHD students and Post-Docs